Physician profile
Bobbak Mansouri
NPI 1053604389
$16,428.24
in general payments reported to CMS, 2019-2025
37 companies · $3,395 in 2025
The $3,395 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $591 · 2021: $1,161 · 2022: $2,887 · 2023: $3,437 · 2024: $3,955 · 2025: $3,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,686.81 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,237.32 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,764.86 | 2019-2025 | |
| Lilly USA, LLC | $1,680.56 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $1,239.94 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $878.32 | 2019-2025 | |
| Pfizer INC. | $810.76 | 2019-2025 | |
| Incyte Corporation | $802.08 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $667.98 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $667.21 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $658.60 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $652.93 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $499.52 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Amgen INC. | $479.93 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $458.61 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $390.52 | 2020-2025 | Absorica Ld, Winlevi, Blu-U |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobbak Mansouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.